Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.18M | $1.46M | $864.00K | $889.00K | $892.00K | $865.00K | $35.69M | $602.00K |
| Gross profit | $10.18M | $1.46M | $864.00K | $889.00K | $892.00K | $865.00K | $35.69M | $602.00K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | $69.63M | $68.57M | $83.53M | $58.90M | $166.15M | $72.48M | $71.74M | $82.16M |
| Selling, general and administrative | $17.55M | $17.18M | $18.40M | $16.93M | $18.92M | $19.30M | $18.12M | $17.42M |
| Operating expenses | $127.45M | $131.71M | $155.63M | $132.95M | $230.22M | $149.29M | $100.28M | $110.73M |
| Operating income | −$117.27M | −$130.25M | −$154.76M | −$132.06M | −$229.32M | −$148.42M | −$64.59M | −$110.13M |
| Operating margin | -1151.8% | -8933.3% | -17912.5% | -14854.8% | -25709.0% | -17158.8% | -181.0% | -18294.0% |
| EBITDA | −$112.99M | −$125.93M | −$149.10M | −$127.63M | −$224.68M | −$143.69M | −$59.75M | −$105.39M |
| Income before taxes | −$90.19M | −$122.09M | −$130.00M | −$105.82M | −$207.26M | −$134.89M | −$36.61M | −$85.07M |
| Income taxes | $960.00K | $839.00K | $614.00K | $619.00K | $1.29M | $1.11M | $700.00K | $876.00K |
| Net income | −$91.15M | −$122.93M | −$130.61M | −$106.44M | −$208.55M | −$136.00M | −$37.31M | −$85.94M |
| Net margin | -895.3% | -8431.5% | -15117.2% | -11973.1% | -23379.9% | -15722.1% | -104.5% | -14276.1% |
| EPS, basic | −$0.94 | −$1.28 | −$1.37 | −$1.17 | −$2.40 | −$1.58 | −$0.44 | −$1.01 |
| EPS, diluted | −$0.94 | −$1.28 | −$1.37 | −$1.17 | −$2.40 | −$1.58 | −$0.44 | −$1.01 |
| Diluted shares | 96.51M | 96.05M | 95.39M | 91.31M | 87.07M | 85.94M | 85.49M | 85.23M |
Figures describe CRISPR Therapeutics shares, not any token. As of Aug 3, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.